In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $26.91 in the last session, down -1.86% from day before closing price of $27.42. In other words, the price has decreased by -$1.86 from its previous closing price. On the day, 1.3 million shares were traded. ACAD stock price reached its highest trading level at $27.5 during the session, while it also had its lowest trading level at $26.55.
Ratios:
We take a closer look at ACAD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.02. For the most recent quarter (mrq), Quick Ratio is recorded 2.94 and its Current Ratio is at 3.02. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on October 21, 2025, initiated with a Buy rating and assigned the stock a target price of $33.
On May 21, 2025, Deutsche Bank Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $35.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.Deutsche Bank initiated its Hold rating on February 11, 2025, with a $22 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 18 ’25 when Schneyer Mark C. sold 10,262 shares for $23.69 per share. The transaction valued at 243,114 led to the insider holds 53,338 shares of the business.
Kihara James sold 4,084 shares of ACAD for $96,754 on Nov 18 ’25. The PRINCIPAL ACCOUNTING OFFICER now owns 25,058 shares after completing the transaction at $23.69 per share. On Nov 10 ’25, another insider, Daly James M, who serves as the Director of the company, sold 30,000 shares for $22.37 each. As a result, the insider received 670,983 and left with 4,041 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 4552683008 and an Enterprise Value of 3760472576. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.31, and their Forward P/E ratio for the next fiscal year is 36.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.35 while its Price-to-Book (P/B) ratio in mrq is 4.96. Its current Enterprise Value per Revenue stands at 3.591 whereas that against EBITDA is 34.672.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.66, which has changed by 0.58864427 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $28.35, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is 6.83%, while the 200-Day Moving Average is calculated to be 21.93%.
Shares Statistics:
According to the various share statistics, ACAD traded on average about 1.64M shares per day over the past 3-months and 1109220 shares per day over the past 10 days. A total of 169.15M shares are outstanding, with a floating share count of 167.35M. Insiders hold about 1.08% of the company’s shares, while institutions hold 99.93% stake in the company. Shares short for ACAD as of 1765756800 were 8681267 with a Short Ratio of 5.30, compared to 1763078400 on 9453950. Therefore, it implies a Short% of Shares Outstanding of 8681267 and a Short% of Float of 8.0299996.
Earnings Estimates
The stock of Acadia Pharmaceuticals Inc (ACAD) is currently being evaluated by 16.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.13, with high estimates of $0.22 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.98 and $0.55 for the fiscal current year, implying an average EPS of $0.82. EPS for the following year is $0.82, with 16.0 analysts recommending between $1.15 and $0.39.
Revenue Estimates
According to 19 analysts, . The current quarter’s revenue is expected to be $293.33M. It ranges from a high estimate of $300M to a low estimate of $284.84M. As of . The current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $259.6MFor the next quarter, 19 analysts are estimating revenue of $284.75M. There is a high estimate of $289.7M for the next quarter, whereas the lowest estimate is $282.11M.
A total of 20 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.07B, resulting in an average revenue estimate of $1.08B. In the same quarter a year ago, actual revenue was $957.8MBased on 19 analysts’ estimates, the company’s revenue will be $1.21B in the next fiscal year. The high estimate is $1.32B and the low estimate is $1.16B.
